Drug firm Dr Reddy's Laboratories announced the launch of generic Paricalcitol injection in the US for treatment associated with chronic kidney disease.
In a filing to BSE today, the company announced the launch of the injection USP in the strengths of two mcg, five mcg and 10 mcg.
The company's product is generic version of AbbVie Inc's Zemplar injections, it added.
"The injection is first Abbreviated New Drug Application (ANDA) product launched in the US after approval from the US Food and Drug Administration," it said in the statement.
"The Zemplar brand and generic had US sales of approximately USD 22.5 million MAT for the most recent 12 months ending July 2016 according to IMS Health," added Dr Reddy's statement.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app